Self-reported use of pharmaceuticals among patients with irritable bowel syndrome in primary care.


BACKGROUND Irritable bowel syndrome (IBS) has an estimated 10%-12% prevalence in industrial countries. Studies from the United States have shown that IBS causes notable financial losses for employers. Due to the lack of pathophysiological markers, only a fraction of the pharmacological management of IBS has focused on etiological mechanisms. We hypothesized… (More)


3 Figures and Tables

Slides referencing similar topics